Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S5 - E20.1 - Drug Development Highlights From EASL Congress 2024: Resmetirom
Description: Naim Alkhouri and Mazen Noureddin join Jörn Schattenberg and Roger Green to discuss some of the new research on resmetirom at the EASL Congress 2024.Mazen begins this discussion by covering a paper he presented on Stephen's behalf, looking at dose-response with resmetirom. The analysis indicated that PDFF and histology improvements at the 100mg dose were greater than at the 80mg dose. Mazen speculates that the higher dose might provide a greater anti-fibrotic response as well, although, in a world where biopsy is not required for prescribing, he doubts the study will ever be done. Jörn not...